Adipose, bone and muscle tissues as new endocrine organs: Role of reciprocal regulation for osteoporosis and obesity development

Hormone Molecular Biology and Clinical Investigation

Volumn 17, Issue 1, 2014, Pages 39-51

  Migliaccio, Silvia ^a   Greco, Emanuela A ^b   Wannenes, Francesca ^a   Donini, Lorenzo M ^b   Lenzi, Andrea ^b  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Obesity; Osteoporosis; Sarcopenia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; BETA ADRENERGIC RECEPTOR; EPIDERMAL GROWTH FACTOR; ESTROGEN; GONADORELIN AGONIST; INTERLEUKIN 6; LEPTIN; MYOSTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RESISTIN; STEROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; ADIPOCYTOKINE; GROWTH FACTOR; SIGNAL PEPTIDE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; BASAL METABOLIC RATE; BODY COMPOSITION; BODY FAT; BONE DEVELOPMENT; BONE MASS; BONE REMODELING; BONE TISSUE; BROWN ADIPOSE TISSUE; CALORIC INTAKE; DISEASE ASSOCIATION; ENERGY EXPENDITURE; ESTROGEN THERAPY; EVIDENCE BASED PRACTICE; EXERCISE; FAT MASS; HUMAN; LEAN BODY WEIGHT; MACROPHAGE; MALNUTRITION; MUSCLE CELL; MUSCLE MASS; MUSCLE TISSUE; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY; BONE DENSITY; FRAGILITY FRACTURE; REGULATORY MECHANISM; RISK FACTOR; ANIMAL; BONE; ENDOCRINE SYSTEM; METABOLISM; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BONE AND BONES; BONE DENSITY; ENDOCRINE SYSTEM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE, SKELETAL; OBESITY; OSTEOPOROSIS;

EID: 84924408004     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0070     Document Type: Review

References (148)

1. Kado DM, Huang MH, Karlamangla AS, Barrett-Connor E, Greendale GA. Hyperkyphotic posture predicts mortality in older community-dwelling men and women: a prospective study. J Am Geriatr Soc 2004;52:1662-7.
2. Rossner S. Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S2-4.
3. Hu FB. Overweight and obesity in women: health risks and consequences. J Women Health (Larchmt) 2003;12: 163-72.
4. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
5. Reid IR. Relationships among body mass, its components, and bone. Bone 2002;31:547-55.
6. NIH Consensus development panel on osteoporosis. J Am Med Assoc 2001;285:785-95.
7. Migliaccio S, Greco EA, Fornari R, Donini LM, Lenzi A. Is obesity in women protective against osteoporosis? Diabetes Metab Syndr Obes 2011;4:273-82.
8. Cagnacci A, Zanin R, Cannoletta M, Generali M, Caretto S, Volpe A. Menopause, estrogens, progestins, or their combination on body weight and anthropometric measures. Fertil Steril 2007;88:1603-8.
9. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003;134:18-27.
10. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;8:37S-41S.
11. Albala C, Yanez M, Devoto E, Sostin C, Zeballos L, Santos JL. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 1996;20:1027-32.
12. Brown S, Rosen CJ. Osteoporosis. Med Clin North Am 2003;87:1039-63.
13. Migliaccio S, Fornari R, Greco EA, Di Luigi L, Lenzi A. New therapeutical horizons in the management of postmenopausal osteoporosis. Aging Clin Exper Res 2013;25:117-9.
14. Migliaccio S, Falcone S, Spera G. Bone modeling and remodeling: from biology to clinical application. Aging Clin Exp Res 2004;16(Suppl):20-2.
15. Goulding A, Jones IE, Taylor RW, Williams SM, Manning PJ. Bone mineral density and body composition in boys with distal forearm fractures: a dual-energy X-ray absorptiometry study. J Pediatr 2001;139:509-15.
16. Kveiborg M, Flyvbjerg A, Rattan SI, Kassem M. Changes in the insulin-like growth factor-system may contribute to in vitro agerelate impaired osteoblast functions. Exp Geronto 2000;35:1061-74.
17. Johansson C, Black D, Johnell O, Oden A, Mellstrom D. Bone mineral density is a predictor of survival. Calcif Tissue Int 1998;63:190-6.
18. Von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106:273-8.
19. Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337-9.
20. Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, Woo J, Baumgartner R, Pillard F, Boirie Y, Chumlea WM, Vellas B. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12:433-50.
21. Janssen I. The epidemiology of sarcopenia. Clin Geriatr Med 2011;27:355-63.
22. Davison KK, Ford ES, Cogswell ME, Dietz WH. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc 2002;50:1802-9.
23. Schrager MA, Kelly VE, Price R, Ferrucci L, Shumway-Cook A. The effects of age on medio-lateral stability during normal and narrow base walking. Gait Posture 2008;28:466-71.
24. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008;11: 693-700.
25. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endoc Metab 1992;75:779-82.
26. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993;8:567-73.
27. Marcus R, Greendale G, Blunt BA, Bush TL, Sherman S, Sherwin R, Wahner H, Wells B. Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res 1994;9:1467-76.
28. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TM, Cundy TF. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 1992;75:45-51.
29. Khosla S, Atkinson EJ, Riggs BL, Melton LJ III. Relationship between body composition and bone mass in women. J Bone Miner Res 1996;11:857-63.
30. Pluijm SM, Visser M, Smit JH, Popp-Snijders C, Roos JC, Lips P. Determinants of bone mineral density in older men and women: body composition as mediator. J Bone Miner Res 2001;16:2142-51.
31. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-6.
32. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR. Estrogen binding, receptor mRNA, and biologic response in osteoblastlike osteosarcoma cells. Science 1988;241:81-4.
33. Migliaccio S, Davis VL, Gibson MK, Gray TK, Korach KS. Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology 1992;130:2617-24.
34. Kim HJ. New understanding of glucocorticoid action in bone cells. BMB Rep 2010;43:524-9.
35. Fukumoto S, Martrin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009;20:230-6.
36. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-5.
37. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
38. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 1999;14:1622-7.
39. Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, Deng HW. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008;23:17-29.
40. Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, Laird N, Brain JD, Cummings SR, Bouxsein ML, Rosen CJ, Xu X. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr 2006;83:146-54.
41. Greco EA, Fornari R, Rossi F, Santiemma V, Prossomariti G, Annoscia C, Aversa A, Brama M, Marini M, Donini LM, Spera G, Lenzi A, Lubrano C, Migliaccio S. Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract 2010;64:817-20.
42. Greco EA, Francomano D, Fornari R, Marocco C, Lubrano C, Papa V, Wannenes F, Di Luigi L, Donini LM, Lenzi A, Aversa A, Migliaccio S. Negative association between trunk fat, insulin resistance and skeleton in obese women. World J Diabetes 2013;4:31-9.
43. Migliaccio S, Francomano D, Bruzziches R, Greco EA, Fornari R, Donini LM, Lenzi A, Aversa A. Trunk fat negatively influences skeletal and testicular functions in obese men: clinical implications for the aging male. Int J Endocrinol 2013;2013:182753.
44. Blum M, Harris SS, Must A, Naumova EN, Phillips SM, Rand WM, Dawson-Hughes B. Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int 2003;73:27-32.
45. Kim KC, Shin DH, Lee SY, Im JA, Lee DC. Relation between obesity and bone mineral density and vertebral fractures in Korean Postmenopausal Women. Yonsei Med J 2010;51:857-63.
46. Castro JP, Joseph LA, Shin JJ, Arora SK, Nicasio J, Shatzkes J, Raklyar I, Erlikh I, Pantone V, Bahtiyar G, Chandler L, Pabon L, Choudhry S, Ghadiri N, Gosukonda P, Muniyappa R, von-Gicyzki H, McFarlane SI. Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutr Metab (Lond) 2005;2:9.
47. Afghani A, Goran MI. Racial differences in the association of subcutaneous and visceral fat on bone mineral content in prepubertal children. Calcif Tissue Int 2006;79:383-8.
48. Reid IR, Legge M, Stapleton JP, Evans MC, Grey AB. Regular exercise dissociates fat mass and bone density in premenopausal women. J Clin Endocrinol Metab 1995;80:1764-8.
49. Reid IR. Therapy of osteoporosis: calcium, vitamin D, and exercise. Am J Med Sci 1996;312:278-86.
50. Manson JE, Martin KA. Postmenopausal hormonereplacement therapy. N Engl J Med 2001;345:34-40.
51. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001;9:622-6.
52. De Gregorio LH, Lacativa PG, Melazzi AC, Russo LA. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol 2006;50:793-801.
53. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004;15:323-8.
54. Gaillard D, Wabitsch M, Pipy B, Negrel R. Control of terminal differentiation of adipose precursor cells by glucocorticoids. J Lipid Res 1991;32:569-79.
55. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000;141:560-3.
56. Mieczkowska A, Baslé MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G proteincoupled receptor 40-dependent mechanism. J Biol Chem 2012;287:23517-26.
57. Drøyvold WB, Nilsen TI, Krüger O, Holmen TL, Krokstad S, Midthjell K, Holmen J. Change in height, weight and body mass index: longitudinal data from the HUNT Study in Norway. Int J Obes 2006;30:935-9.
58. Koster A, Ding J, Stenholm S, Caserotti P, Houston DK, Nicklas BJ, You T, Lee JS, Visser M, Newman AB, Schwartz AV, Cauley JA, Tylavsky FA, Goodpaster BH, Kritchevsky SB, Harris TB. Health ABC study. Does the amount of fat mass predict age-related loss of lean mass, muscle strength, and musclequality in older adults? J Gerontol A Biol Sci Med Sci 2011;66:888-95.
59. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi M, Rantanen T, Guralnik JM, Ferrucci L. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003;95:1851-60.
60. Bassey EJ. Longitudinal changes in selected physical capabilities: muscle strength, flexibility and body size. Age Ageing 1998;27(Suppl 3):12-16.
61. Frontera WR, Zayas AR, Rodriguez N. Aging of human muscle: understanding sarcopenia at the single muscle cell level. Phys Med Rehabil Clin N Am 2012;23:201-7.
62. Morio B, Hocquette JF, Montaurier C, Boirie Y, Bouteloup-Demange C, McCormack C, Fellmann N, Beaufrère B, Ritz P. Muscle fatty acid oxidative capacity is a determinant of whole body fat oxidation in elderly people. Am J Physiol Endocrinol Metab 2001;280:E143-9.
63. Coin A, Perissinotto E, Enzi G, Zamboni M, Inelmen EM, Frigo AC, Manzato E, Busetto L, Buja A, Sergi G. Predictors of low bone mineral density in the elderly: the role of dietary intake, nutritional status and sarcopenia. Eur J Clin Nutr 2008;62:802-9.
64. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011;12:249-56.
65. Horber FF, Gruber B, Thomi F, Jensen EX, Jaeger P. Effects of sex and age on bone mass, body composition and fuel metabolism in humans. Nutrition 1997;13:524-34.
66. Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E, Harris TB. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc 2002;50:897-904.
67. Elia M, Stratton R, Stubbs J. Techniques for the study of energy balance in man. Proc Nutr Soc 2003;62:529-37.
68. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 2003;58:M911-6.
69. Morley JE, Malmstrom TK. Frailty, sarcopenia, and hormones. Endocrinol Metab Clin North Am 2013;42:391-405.
70. Doherty TJ. Invited review: aging and sarcopenia. J Appl Physiol (1985) 2003;95:1717-27.
71. Schroeder ET, Castaneda-Sceppa C, Wang Y, Binder EF, Kawakubo M, Stewart Y, Storer T, Roubenoff R, Bhasin S, Yarasheski KE, Sattler FR, Azen SP. Hormonal regulators of muscle and metabolism in aging (HORMA): design and conduct of a complex, double masked multicenter trial. Clin Trials 2007;4:560-71.
72. Blair SN, LaMonte MJ, Nichaman MZ. The evolution of physical activity recommendations: how much is enough? Am J Clin Nutr 2004;79:913S-20S.
73. Duvigneaud N, Matton L, Wijndaele K, Deriemaeker P, Lefevre J, Philippaerts R, Thomis M, Delecluse C, Duquet W. Relationship of obesity with physical activity, aerobic fitness and muscle strength in Flemish adults. J Sports Med Phys Fitness 2008;48:201-10.
74. Zhou Q, Du J, Hu Z, Walsh K, Wang XH. Evidence for adiposemuscle cross talk: opposing regulation of muscle proteolysis by adiponectin and Fatty acids. Endocrinology 2007;148: 5696-705.
75. Frimel TN, Sinacore DR, Villareal DT. Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults. Med Sci Sports Exerc 2008;40:1213-9.
76. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 2004;12: 1995-2004.
77. Koster A, Ding J, Stenholm S, Caserotti P, Houston DK, Nicklas BJ, You T, Lee JS, Visser M, Newman AB, Schwartz AV, Cauley JA, Tylavsky FA, Goodpaster BH, Kritchevsky SB, Harris TB; Health ABC study. Does the amount of fat mass predict age-related loss of lean mass, muscle strength, and musclequality in older adults? J Gerontol A Biol Sci Med Sci 2011;66:888-95.
78. Gomez-Ambrosi J, Rodriguez A, Catalan V, Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg 2008;18:1134-43.
79. Takeda S. Effect of obesity on bone metabolism. Clin Calcium 2008;18:632-7.
80. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem 2006;98:251-66.
81. Vettor R, Milan G, Franzin C, Sanna M, De Coppi P, Rizzuto R, Federspil G. The origin of intermuscular adipose tissue and its pathophysiological implications. Am J Physiol Endocrinol Metab 2009;297:E987-98.
82. Buehring B, Binkley N. Myostatin-the holy grail for muscle, bone, and fat? Current Osteoporos Rep 2013;11:407-14.
83. Smorlesi A, Frontini A, Giordano A, Cinti S. The adipose organ: white-brown adipocyte plasticity and metabolic inflammation. Obes Rev 2012;13(Suppl 2):83-96.
84. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med 2013;19:1252-63.
85. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92:73-78.
86. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51.
87. Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004;12:962-71.
88. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008;14:222-31.
89. Magni P, Dozio E, Galliera E, Ruscica M, Corsi MM. Molecular Aspects of Adipokine-Bone Interactions. Curr Mol Med 2010;10:522-32.
90. Berthier MT, Paradis AM, Tchernof A. The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet 2003;48:14-9.
91. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
92. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 1994;331:1056-61.
93. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-98.
94. Cooke PS, Heine PA, Taylor JA, Lubahn DB. The role of estrogen and estrogen receptor-alpha in male adipose tissue. Mol Cell Endocrinol 2001;178:147-54.
95. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004;89:61-70.
96. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET. Menopause, central body fatness, and insulin resistance: Effects of hormone-replacement therapy. Coron Artery Dis 1998;9:503-11.
97. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001;39:125-32.
98. Jensen LB, Vestergaard P, Hermann AP, Gram J, Eiken P, Abrahamsen B, Brot C, Kolthoff N, Sørensen OH, Beck-Nielsen H, Nielsen SP, Charles P, Mosekilde L. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003;18:333-42.
99. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
100. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001;2:165-71.
101. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999;130:671-80.
102. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
103. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
104. Wisse BE, Schwartz MW. Role of melanocortins in control of obesity. Lancet 2001;358:857-9.
105. Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 2004;19:546-51.
106. Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 1998;63:456-58.
107. Yamauchi M, Sugimoto T, Yamaguchi T. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 2001;55:341-7.
108. Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 2001;86:1884-7.
109. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res 2002;17:1563-9.
110. Thomas T. Leptin: a potential mediator for protective effects of fat mass on bone tissue. Joint Bone Spine 2003; 70:18-21.
111. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004;4: 295-300.
112. Martin A, de Vittoris R, David V, Moraes R, Bégeot M, Lafage-Proust MH, Alexandre C, Vico L, Thomas T. Leptin modulate both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 2005;146:3652-9.
113. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002;175:405-15.
114. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
115. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005;37:601-6.
116. Lean ME. Brown adipose tissue in humans. Proc Nutr Soc 1989;48:243-56.
117. Enerbäck S. Human brown adipose tissue. Cell Metab 2010;11:248-52.
118. Van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009;360:1500-8.
119. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerbäck S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-25.
120. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360:1509-17.
121. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scimè A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008;454:961-7.
122. Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev 2013;27:234-50.
123. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhal-Chaieb L, Turcotte E, Carpentier AC, Richard D. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab 2011;96:192-9.
124. Lee P, Brychta RJ, Collins MT, Linderman J, Smith S, Herscovitch P, Millo C, Chen KY, Celi FS. Cold-activated brown adipose tissue is an independent predictor of higher bone mineral density in women. Osteoporos Int 2013;24:1513-8.
125. Ponrartana S, Aggabao PC, Hu HH, Aldrovandi GM, Wren TA, Gilsanz V. Brown adipose tissue and its relationship to bone structure in pediatric patients. J Clin Endocrinol Metab 2012;97:2693-8.
126. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPAR-insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-55.
127. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC. Peroxisome proliferatoractivated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50:1087-94.
128. Rodriguez JP, Montecinos L, Rios S, Reyes P, Martinez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem 2000;79:557-65.
129. Sekiya I, Larson BL, Vuoristo JT, Cui JG, Prockop DJ. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res 2004;19:256-64.
130. Aubin JE. Bone stem cells. J Cell Biochem 1998;(Suppl 30-31):73-82.
131. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenicdisease and aging connection. Med Hypotheses 2001;56:702-8.
132. Cheleuitte D, Mizuno S, Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab 1998;83:2043-51.
133. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPARgamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004;3:379-89.
134. Kajkenova O, Lecka-Czernik B, Gubrij I, Hauser SP, Takahashi K, Parfitt AM, Jilka RL, Manolagas SC, Lipschitz DA. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res. 1997;12:1772-9.
135. Duque G, Macoritto M, Kremer R. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology 2004;5:421-9.
136. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
137. Bennett CN, Ross SE, Longo KA. Regulation of Wnt signaling during adipogenesis. J Biol Chem 2002;277:30998-1004.
138. Zhou S, Eid K, Glowacki J. Cooperation between TGFbeta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res 2004;19:463-70.
139. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 2004; 19:841-52.
140. Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 2010;10:56-63.
141. Yue H, He JW, Zhang H, Wang C, Hu WW, Gu JM, Ke YH, Fu WZ, Hu YQ, Li M, Liu YJ, Wu SH, Zhang ZL. Contribution of myostatin gene polymorphisms to normal variation in lean mass, fat mass and peak BMD in Chinese male offspring. Acta Pharmacol Sin 2012;33:660-7.
142. Mitchell AD, Wall RJ. In vivo evaluation of changes in body composition of transgenic mice expressing the myostatin pro domain using dual energy X-ray absorptiometry. Growth Dev Aging 2007;70:25-37.
143. Artaza JN, Bhasin S, Magee TR, Reisz-Porszasz S, Shen R, Groome NP, Meerasahib MF, Gonzalez-Cadavid NF. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology 2005;146:3547-57.
144. Cohen A, Dempster DW, Recker RR, Lappe JM, Zhou H, Zwahlen A, Müller R, Zhao B, Guo X, Lang T, Saeed I, Liu XS, Guo XE, Cremers S, Rosen CJ, Stein EM, Nickolas TL, McMahon DJ, Young P, Shane E. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab 2013;98:2562-72.
145. Russell M, Mendes N, Miller KK, Rosen CJ, Lee H, Klibanski A, Misra M. Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab 2010;95:1247-55.
146. Compston JE, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, Díez-Pérez A, Lindsay R, Saag KG, Netelenbos JC, Gehlbach S, Hooven FH, Flahive J, Adachi JD, Rossini M, Lacroix AZ, Roux C, Sambrook PN, Siris ES, Glow Investigators. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med 2011;124:1043-50.
147. Donini LM, Poggiogalle E, Migliaccio S, Aversa A, Pinto A. Body composition in sarcopenic obesity: systematic review of the literature. Mediterranean J Nutr Metab 2013:6:191-8.
148. Migliaccio S, Greco EA, Fornari R, Donini LM, Lenzi A. Is obesity in women protective against osteoporosis? Diabetes Metab Syndr Obes 2011;4:273-82.